Two adjacent domains (141-150 and 151-160) of apoE covalently linked to a class A amphipathic helical peptide exhibit opposite atherogenic effects

Atherosclerosis

Volumn 213, Issue 2, 2010, Pages 449-457

  Nayyar, Gaurav ^a   Handattu, Shaila P ^a   Monroe, Candyce E ^a   Chaddha, Manjula ^a   Datta, Geeta ^a   Mishra, Vinod K ^a   Keenum, Tamara D ^a   Palgunachari, Mayakonda N ^a   Garber, David W ^a   Anantharamaiah, G M ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Apolipoproteins; Atherosclerosis; Cholesterol; Lipid oxidation; Peptides

Indexed keywords

AMIDE; ANTILIPEMIC AGENT; APOLIPOPROTEIN E; ARYLDIALKYLPHOSPHATASE 1; CHOLESTEROL; HEPARIN BINDING PROTEIN; LIPID HYDROPEROXIDE; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; AORTA SINUS; ARTICLE; ATHEROGENESIS; BLOOD SAMPLING; CELL STRAIN HEPG2; CHOLESTEROL BLOOD LEVEL; CIRCULAR DICHROISM; CONTROLLED STUDY; COVALENT BOND; DRUG PROTEIN BINDING; ELECTROPHORETIC MOBILITY; ENDOTHELIUM CELL; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIPID OXIDATION; MONOCYTE; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; APOLIPOPROTEINS E; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; CHOLESTEROL; ENDOTHELIAL CELLS; FEMALE; HEP G2 CELLS; HEPARAN SULFATE PROTEOGLYCANS; HUMANS; LIPOPROTEINS; LIPOPROTEINS, LDL; MICE; MONOCYTES; PEPTIDE FRAGMENTS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; TRIGLYCERIDES;

EID: 78649727746     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.09.030     Document Type: Article

References (31)

1. Piedrahita J.A., Zhang S.H., Hagaman J.R., Oliver P.M., Maeda N. Generation of mice carrying a mutant apolipoprotein E gene inactivated by gene targeting in embryonic stem cells. Proc Natl Acad Sci USA 1992, 89:4471-4475.
2. Nakashima Y., Plump A.S., Raines E.W., Breslow J.L., Ross R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler Thromb Vasc Biol 1994, 14:133-140.
3. Shimano H., Yamada N., Katsuki M., et al. Plasma lipoprotein metabolism in transgenic mice overexpressing apolipoprotein E. Accelerated clearance of lipoproteins containing apolipoprotein B. J Clin Invest 1992, 90:2084-2091.
4. Mahley R.W., Weisgraber K.H., Hussein M.M., et al. Intravenous infusion of apolipoprotein E accelerates clearance of plasma lipoproteins in rabbits. J Clin Invest 1989, 83:2125-2130.
5. Grundy S.M. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation 2002, 106:2526-2529.
6. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
7. Weisgraber K.H. Apolipoprotein E: structure-function relationships. Adv Protein Chem 1994, 45:249-302.
8. Bradley W.A., Gilliam E.B., Gotto A.M., Gianturco S.H. Apolipoprotein E degradation in human very low density lipoproteins by protease(s): chemical and biological consequences. Biochem Biophys Res Commun 1982, 109:1360-1367.
9. Datta G., Chaddha M., Garber D.W., et al. The receptor binding domain of apolipoprotein E, linked to a model class A amphipathic helix, enhances internalization and degradation of LDL by fibroblasts. Biochemistry 2000, 39:213-220.
10. Anantharamaiah G.M., Jones J.L., Brouillette C.G., et al. Studies of synthetic peptide analogs of the amphipathic helix. Structure of complexes with dimyristoyl phosphatidylcholine. J Biol Chem 1985, 260:10248-10255.
11. Datta G., Garber D.W., Chung B.H., et al. Cationic domain 141-150 of apoE covalently linked to a class A amphipathic helix enhances atherogenic lipoprotein metabolism in vitro and in vivo. J Lipid Res 2001, 42:959-966.
12. Garber D.W., Handattu S., Aslan I., Datta G., Chaddha M., Anantharamaiah G.M. Effect of an arginine-rich amphipathic helical peptide on plasma cholesterol in dyslipidemic mice. Atherosclerosis 2003, 168:229-237.
13. Gupta H., White C.R., Handattu S., et al. Apolipoprotein E mimetic peptide dramatically lowers plasma cholesterol and restores endothelial function in Watanabe heritable hyperlipidemic rabbits. Circulation 2005, 111:3112-3118.
14. 2. Atherosclerosis 2010, 208:131-141.
15. Cardin A.D., Hirose N., Blankenship D.T., et al. Binding of a high reactive heparin to human apolipoprotein E: identification of two heparin-binding domains. Biochem Biophys Res Commun 1986, 134:783-789.
16. Palgunachari M.N., Mishra V.K., Lund-Katz S., et al. Only the two end helixes of eight tandem amphipathic helical domains of human apo A-I have significant lipid affinity: implications for HDL assembly. Arterioscler Thromb Vasc Biol 1996, 16:328-338.
17. Morrisett J.D., David J.S.K., Pownall H.J., Gotto A.M. Interaction of an apolipoprotein (apoLP-alanine) with phosphatidylcholine. Biochemistry 1973, 12:1290-1299.
18. Schumaker V.N., Puppione D.L. Sequential flotation ultracentrifugation. Methods Enzymol 1986, 128:155-170.
19. Handattu S.P., Garber D.W., Horn D.C., et al. ApoA-I mimetic peptides with differing ability to inhibit atherosclerosis also exhibit differences in their interactions with membrane bilayers. J Biol Chem 2007, 282:1980-1988.
20. Goldstein J.L., Basu S.K., Brown M.S. Receptor-mediated endocytosis of low-density lipoprotein in cultured cells. Methods Enzymol 1983, 98:241-260.
21. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951, 193:265-275.
22. El-Saadani M., Esterbauer H., El-Sayed M., Goher M., Nassar A.Y., Jurgens G. A spectrophotometric assay for lipid peroxides in serum lipoproteins using a commercially available reagent. J Lipid Res 1989, 30:627-630.
23. Ji Z.S., Sanan D.A., Mahley R.W. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J Lipid Res 1995, 36:583-592.
24. Garber D.W., Datta G., Chaddha M., et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 2001, 42:545-552.
25. Palinski W., Ord V.A., Plump A.S., Breslow J.L., Steinberg D., Witztum J.L. ApoE-deficient mice are a model of lipoprotein oxidation in atherogenesis. Demonstration of oxidation-specific epitopes in lesions and high titers of autoantibodies to malondialdehyde-lysine in serum. Arterioscler Thromb Vasc Biol 1994, 14:605-616.
26. Anantharamaiah G.M. Synthetic peptide analogs of apolipoproteins. Methods Enzymol 1986, 128:627-647.
27. Segrest J.P., Garber D.W., Brouillette C.G., Harvey S., Anantharamaiah G.M. The amphipathic α helix: a multifunctional structural motif in plasma apolipoproteins. Adv Protein Chem 1994, 45:303-363.
28. Datta G., Chaddha M., Hama S., et al. Effects of increasing hydrophobicity on the physical-chemical and biological properties of a class A amphipathic helical peptide. J Lipid Res 2001, 42:1096-1104.
29. Datta G., Epand R.F., Epand R.M., et al. Aromatic residue position on the nonpolar face of class A amphipathic helical peptides determines biological activity. J Biol Chem 2004, 279:26509-26517.
30. Anantharamaiah G.M., Navab M., Reddy S.T., et al. Synthetic peptides: managing lipid disorders. Curr Opin Lipidol 2006, 17:233-237.
31. Anantharamaiah G.M., Mishra V.K., Garber D.W., et al. Structural requirements for antioxidative and anti-inflammatory properties of apolipoprotein A-I mimetic peptides. J Lipid Res 2007, 48:1915-1923.